On a pre-clinical level, an association between the overexpression of ACTL6A and cisplatin resistance has been observed in lung and ovarian cancer cell lines and lung cancer xenografts, which has been explained by increased repair of cisplatin DNA adducts mediated by ACTL6A. This evidence concerns the gene ACTL6A and lung carcinoma.